OncoCyte reports Q3 EPS (98c), consensus (44c)

Like
Comment
Favorite

OncoCyte reports Q3 EPS (98c), consensus (44c)

TIPRANKS2024-11-12

Oncocyte’s (OCX) cash, cash equivalents, and restricted cash balance at the end of the third quarter was approximately $5.1M down $5.9M sequentiall...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

23:45
Sunac Services - Proposed to Declare a Final Dividend of RMB14.3 Cents per Share
23:45
Sunac Services Holdings FY Gross Margin 21.9%
23:45
Sunac Services Holdings FY Net Income RMB -433.1 Million
23:45
BENCHMARK 10-YR JUNE JGB FUTURES DOWN 0.18 PTS AT 137.66
23:45
JAPAN'S NIKKEI AVERAGE FUTURES UP 1.1%

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2483106322?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-13 05:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483106322","market":"fut","top_or_hot":-1,"title":"OncoCyte reports Q3 EPS (98c), consensus (44c)","media":"TIPRANKS","content":"<div>\n<p>Oncocyte’s (OCX) cash, cash equivalents, and restricted cash balance at the end of the third quarter was approximately $5.1M down $5.9M sequentiall...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/oncocyte-reports-q3-eps-98c-consensus-44c?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoCyte reports Q3 EPS (98c), consensus (44c)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoCyte reports Q3 EPS (98c), consensus (44c)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 05:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/the-fly/oncocyte-reports-q3-eps-98c-consensus-44c?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oncocyte’s (OCX) cash, cash equivalents, and restricted cash balance at the end of the third quarter was approximately $5.1M down $5.9M sequentiall...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/oncocyte-reports-q3-eps-98c-consensus-44c?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.tipranks.com/news/the-fly/oncocyte-reports-q3-eps-98c-consensus-44c?utm_source=itigerup.com&utm_medium=referral","article_id":"2483106322","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncocyte-reports-q3-eps-98c-consensus-44c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483106322","pubTimestamp":1731448291,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Oncocyte’s (OCX) cash, cash equivalents, and restricted cash balance at the end of the third quarter was approximately $5.1M down $5.9M sequentiall...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OCX":"OncoCyte Corporation"},"translate_title":"OncoCyte报告第三季度EPS(98c)，共识(44c)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCX":1},"content_text":"Oncocyte’s (OCX) cash, cash equivalents, and restricted cash balance at the end of the third quarter was approximately $5.1M down $5.9M sequentiall...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}